All In Biotech

Drug Trial Radar · NCT06567470

A Study With CIT-013 in RA Patients

A Phase IIa Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Trial To Investigate The Effects Of Three Dose Levels Of CIT-013 On Disease Activity In Patients With Moderately Active Rheumatoid Arthritis.

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

96

Actual

Start

Jul 29, 2025

Primary completion

Jul 2, 2026

Study completion Aug 11, 2026

Sponsor

Lead sponsor
Citryll BVIndustry
Sponsor type
Industry
First posted
Aug 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if CIT-013 works to treat rheumatoid arthritis in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Does CIT-013 lower the disease activity of RA patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of RA. Participants will: Take receive CIT-013 or placebo every other week for 6 weeks and 50 mg CIT-013 for 6 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period

Conditions

  • Rheumatoid Arthritis

Interventions

  • CIT-013 low doseDrug

    Subcutaneous injection

  • CIT-013 high doseDrug

    Subcutaneous injection

  • PlaceboDrug

    Subcutaneous injection

  • CIT-013 medium doseDrug

    CIT-013 medium dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change in DAS28-CRP at week 6 compared to baselineTime frame: week 6

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • Site BE-01

    Leuven, Belgium

  • DE-04

    Bamberg, Germany

  • DE-05

    Berlin, Germany

  • DE-01

    München, Germany

  • DE-02

    München, Germany

  • NL-05

    Leeuwarden, Netherlands

  • NL-03

    Nijmegen, Netherlands

  • NL-01

    Rotterdam, Netherlands

  • PL-01

    Bialystok, Poland

  • PL-07

    Krakow, Poland

  • PL-03

    Lublin, Poland

  • PL-02

    Poznan, Poland

  • PL-05

    Torun, Poland

  • PL-04

    Warsaw, Poland

  • ES-02

    A Coruña, Spain

  • ES-04

    Barcelona, Spain

  • ES-05

    Barcelona, Spain

  • ES-06

    Madrid, Spain

  • ES-01

    Santander, Spain

  • ES-03

    Santiago de Compostela, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.